The investigators conducted a validation study for the Montreal Cognitive Assessment
      (MoCA)-XpressO compared to the digital-MoCA test (version 8.1) as the gold standard.
      Participants were recruited from the MoCA clinic and a family practice. Ethics approval was
      received, and all participants provided informed consent. A crossover study design was
      applied to the MoCA-XpressO and the digital-MoCA test; participants were randomized for the
      order of administration. The investigators only recruited participants who did not complete a
      MoCA test during the 3 months prior to the study. A logistic regression model was built, and
      the accuracy of the model was evaluated by the sensitivity, specificity, and area under the
      Receiver Operating Characteristic (ROC) curve.

Validation of a Digital Self-Administered Cognitive Screening Tool: MoCA-XpressO

Cognitive Impairment

Cognitive Change

Cognitive Deficit

Assessment, Self

Introduction:

      The MoCA XpressO is a self-administered medical digital cognitive screening test. This test
      can help individuals assess whether they should have concerns regarding their cognition and
      should bring these concerns up to their physician. The test can be administered in an empty
      office in the clinic, or in the comfort of the patient's home.

      The MoCA Classic test was first published in 2005 by Nasreddine et al. (The Montreal
      Cognitive Assessment, MoCA: A Brief Screening Tool for Mild Cognitive Impairment. J Am
      Geriatr Soc, 2005, 53:695-9.) The MoCA Classic test (version 8.2) is a one-page 30-point test
      administered in 10 minutes. The test and administration instructions are freely accessible at
      www.mocatest.org. The test is available in over 55 languages and dialects. The MoCA Classic
      assesses several cognitive domains. The short-term memory recall task (5 points) involves two
      learning trials of five nouns and delayed recall after approximately 5 minutes. Visuospatial
      abilities are assessed using a clock-drawing task (3 points) and a three-dimensional cube
      copy (1 point). Multiple aspects of executive functions are assessed using an alternation
      task adapted from the trail-making B task (1 point), a phonemic fluency task (1 point), and a
      two-item verbal abstraction task (2 points). Attention, concentration and working memory are
      evaluated using a target detection task (1 point), a serial subtraction task (3 points), and
      a forward and backward digit sequence task (1 point each). Language is assessed using a
      three-item confrontation naming task with low- familiarity animals (3 points), a two-item
      syntactically complex sentence repetition task (2 points), and the aforementioned fluency
      task. Finally, orientation to time and place is evaluated (6 points).

      Study objectives/purpose:

      This study seeks to validate the MoCA XpressO self-administered digital test compared to the
      MoCA Classic test for adults aged 50+. The study's goal is to confirm its performance as a
      viable screening tool to flag concerns regarding cognition in this population.

      Objectives and Hypotheses:

      Primary Objective: establish validity by comparing the MoCA XpressO vs. the digital MoCA
      Classic test.

      Validity Outcome 1: Correlation between the total score of MoCA XpressO and the total score
      of the digital MoCA Classic test.

      Hypothesis 1: There will be a significant correlation between the total scores of the MoCA
      XpressO and MoCA Classic test.

      Secondary Objective: explore the users' experience of the MoCA XpressO test through
      subjective feedback from the participant.

      Outcome 2: subjective feedback about user experience for participant (Likert Scale)
      Hypothesis 2: user experience will be rated high (>=4) on a Likert scale 1-5.

      Additional exploratory measures/data:

      Demographic information (age, level of education etc.); diagnosis; previous MMSE or MoCA
      score if available; frequency of technological use

      Study Sample: the target number of participants is 100. Participants will be recruited from
      the MoCA Memory Clinic and Institute and the Cornwall family practice clinic. Participants in
      this study will consist of adults age 50 and over, with no restrictions to sex, gender, or
      ethnicity. There will be an equal number of participants with normal cognition, mild
      cognitive impairment, and mild AD. They must speak English or French and have at least 6
      years of formal schooling.

      Study locations: 2 clinical sites will recruit potentially eligible participants. (1) MoCA
      Clinic and Institute, Greenfield Park, Québec, Canada; and (2) Family Medicine Practice,
      Cornwall, Ontario, Canada

      Randomization:

      The order of administration of the MoCA XpressO and the digital MoCA Classic test will be
      determined randomly so that each test will have similar chances of being first, or second.
      The same rater will be performing the MoCA Classic test in each clinic participating in the
      validation study.

      Blinding: The participants are blinded to the screening test that is being studied. The
      researcher doing the analysis will be blinded to the order of randomization.

MoCA-Xpresso

Montreal Cognitive Assessment (MoCA) XpressO: Validation of a Digital Self-administered Cognitive Pre-screening Tool for the General Adult Population

Correlation between the total score of MoCA XpressO and the total score of the Digital MoCA Classic

Correlation between the scores of the sub-tests on MoCA XpressO and the scores of the sub-tests on the Digital MoCA Classic

Participants in the study will complete the MoCA-Xpresso test before the digital-MoCA classic test.

Participants in the study will complete the digital-MoCA classic test before the MoCA-Xpresso test.

Validation of a Digital Self-Administered Cognitive Screening Tool: MoCA-XpressO

About this trial

Study ID

Status

Type

Phase

Placebo

Accepting

Trial Timing

What is this trial about?

What are the participation requirements?

Locations

Location

Status